about
Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data.Maternal use of antipsychotics in early pregnancy and delivery outcome.Combined use of selective serotonin reuptake inhibitors and sedatives/hypnotics during pregnancy: risk of relatively severe congenital malformations or cardiac defects. A register studyThe use of central nervous system active drugs during pregnancy.Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression.Enantioselective analysis of citalopram and metabolites in adolescents.Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting.Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997.Therapeutic drug monitoring of ziprasidone in a clinical treatment setting.[Easier for students to reproduce facts than to draw their own conclusions].Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour.Drug use in pregnant women-a pilot study of the coherence between reported use of drugs and presence of drugs in plasma.Sedative and hypnotic drugs—Fatal and non-fatal reference blood concentrationsTherapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patientsTherapeutic drug monitoring of sertraline: variability factors as displayed in a clinical settingNeonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy
P50
Q33521786-C362E1FE-FF79-4FF2-BF51-ABC41D8E2695Q34591997-29562673-C671-4BC4-A7B7-15E068CA33A9Q36649868-9A241445-A98A-45C7-8D90-0535E9E5D17AQ37280003-02F9DDE7-8CE8-4541-BAC8-4DB488545837Q40496609-9F6F4F96-F636-49A0-AEF0-90F142F8A2CCQ43860987-F2FE2FE4-4494-4E9D-B3E7-376305086E73Q44097682-9D9204FC-C748-4EF4-8121-0712F9FD7AC0Q44376824-69527166-1512-42F5-B9AC-BBEA51E3137AQ44955519-AA13B009-7FB7-456A-BA0F-814D3D56603BQ46174709-718D8378-2EDC-4E80-89C3-2B7D4A605C5DQ46204187-CDEC9FB3-CD92-431B-B7F9-83457FE02682Q47271835-BAB9B11A-C76D-466D-8C01-A979ABDB502FQ58454864-C94C2617-42A3-4CC9-8545-5DE623CB1309Q73818130-BAC02C08-313B-4EDE-90A9-5AFB938CDDBBQ74171155-454B3FB0-B9C8-4601-BA9B-42F96F674BCDQ84881130-430467D9-962F-432F-86C5-8AB43600D6B3
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Margareta Reis
@ast
Margareta Reis
@en
Margareta Reis
@es
Margareta Reis
@nl
type
label
Margareta Reis
@ast
Margareta Reis
@en
Margareta Reis
@es
Margareta Reis
@nl
prefLabel
Margareta Reis
@ast
Margareta Reis
@en
Margareta Reis
@es
Margareta Reis
@nl
P106
P1153
7102676405
P21
P31
P496
0000-0002-6041-0744